Studies have demonstrated that HER2-positive breast cancer cells secrete exosomes containing high levels of activated HER2, and these exosomes can directly bind to trastuzumab, a drug that targets HER2, thereby reducing the efficacy of the treatment [33]. Here, ERBB2 is linked to breast carcinoma.